Filana Therapeutics, Inc. (FLNA)
Nasdaq · Healthcare · Biotechnology
$0.8698−6.56%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $42.0M
- 52-week range
- $0.67 – $4.98
- 52-week change
- −72.81%
- EPS (trailing)
- −$0.87
- Analyst rating
- 1.5 Strong buy
- Next earnings
- Oct 29, 2026
Fiscal year to Dec 2025
- Net income
- −$91.0M
- Diluted EPS
- −$1.88
- Free cash flow
- −$32.8M
From the company’s annual report on SEC EDGAR.
About Filana Therapeutics, Inc.
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood. The company was formerly known as Cassava Sciences, Inc. and changed its name to Filana Therapeutics, Inc. in March 2026. The company was incorporated in 1998 and is based in Austin, Texas.
Headquarters: Austin, United States · 17 employees · filanatx.com